Skip Navigation LinksHome > January 2014 - Volume 33 - Issue 1 > Pharmacokinetics and 48-week Safety and Antiviral Activity o...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3182a1126a
HIV Reports

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

Fortuny, Claudia MD*; Duiculescu, Dan MD; Cheng, Katharine MD; Garges, Harmony P. MD§; Cotton, Mark MD; Tamarirt, Desamparados Pérez MD; Ford, Susan L. PharmD§; Wire, Mary Beth PharmD§; Givens, Naomi MSc; Ross, Lisa L. MS§; Lou, Yu MS§; Perger, Teodora MD; Sievers, Jörg DPhil

Open Access
Supplemental Author Material
Collapse Box


Background: Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor–naïve and -experienced HIV-1–infected children.

Methods: Serial pharmacokinetic samples were collected at week 2 and predose samples every 4–12 weeks. Safety and plasma HIV-1 RNA were monitored every 4–12 weeks.

Results: Twenty protease inhibitor–naïve 2- to <6-year-old subjects received antiretroviral treatment including unboosted fosamprenavir twice-daily, whereas 89 protease inhibitor–naïve and -experienced 2- to 18-year-old subjects received fosamprenavir/ritonavir-containing therapy twice-daily. Median fosamprenavir exposure was 891 days (range 15–1805 days), with 88% exposed >48 weeks. Twice-daily doses of fosamprenavir/ritonavir 23/3 mg/kg in 2- to <6-year olds, 18/3 mg/kg in ≥6-year olds and 700/100 mg in adolescents achieved plasma amprenavir exposures comparable with or higher than 700/100 mg twice-daily in adults while fosamprenavir 30 mg/kg twice-daily in 2- to <6-year olds led to exposures higher than 1400 mg twice-daily in adults. The proportion of subjects with HIV-1 RNA <400 copies/mL at week 48 was 60% for fosamprenavir and 53–74% for fosamprenavir/ritonavir (intent-to-treat [exposed], snapshot analysis). Median increases in absolute and relative (percentage) CD4 counts from baseline to week 48 occurred in both the fosamprenavir (340 cells/mm3; 8%) and fosamprenavir/ritonavir group (190 cells/mm3; 8%). The most common adverse events were vomiting, cough, and diarrhea; 18 subjects experienced serious adverse events, including 9 with suspected abacavir hypersensitivity.

Conclusions: Fosamprenavir regimens administered to HIV-1–infected children aged 2–18 years were generally well-tolerated and provided sustained antiviral activity over 48 weeks, with plasma amprenavir exposures comparable with or higher than adults.

© 2014 by Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.